Contrasting Passage Bio (NASDAQ:PASG) & Big Cypress Acquisition (OTCMKTS:BCYP)

Passage Bio (NASDAQ:PASG) and Big Cypress Acquisition (OTCMKTS:BCYP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Passage Bio and Big Cypress Acquisition, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	0	0	3	0	3.00
Big Cypress Acquisition	0	0	0	0	0.00

Passage Bio presently has a consensus target price of $9.00, indicating a potential upside of 1,634.10%. Given Passage Bio’s stronger consensus rating and higher possible upside, research analysts plainly believe Passage Bio is more favorable than Big Cypress Acquisition.

Earnings & Valuation

This table compares Passage Bio and Big Cypress Acquisition”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$102.06 million	($1.17)	-0.44
Big Cypress Acquisition	N/A	N/A	-$10,000.00	N/A	N/A

Profitability

This table compares Passage Bio and Big Cypress Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-72.53%	-52.10%
Big Cypress Acquisition	N/A	N/A	N/A

Insider & Institutional Ownership

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 60.2% of Big Cypress Acquisition shares are held by institutional investors. 4.3% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

About Passage Bio

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About Big Cypress Acquisition

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.